Levetiracetam Induced Acute Psychosis in a Patient with Juvenile Myoclonic Epilepsy

Abhishek Juneja¹* and Kuljeet Singh Anand²

¹Consultant Neurologist, Maharaja Agrasen Hospital, New Delhi, India
²Professor, Department of Neurology, Dr RML Hospital, New Delhi, India

*Corresponding Author: Abhishek Juneja, Consultant Neurologist, Maharaja Agrasen Hospital, New Delhi, India.

Received: February 04, 2021; Published: February 27, 2021

Citation: Abhishek Juneja and Kuljeet Singh Anand. “Levetiracetam Induced Acute Psychosis in a Patient with Juvenile Myoclonic Epilepsy”. Acta Scientific Neurology 4.5 (2021): 11-12.

Abstract

  We report a case of a 22 year old female patient who presented with altered behaviour in the form of anxiety, irritability and agitation for two days. Patient was a diagnosed case of juvenile myoclonic epilepsy for past 10 years on valproate therapy. Patient had been switched to Levetiracetam (1500 mg daily) two weeks back in view of valproate induced side effects. Formal psychiatric evaluation suggested acute psychosis possibly Levetiracetam induced. Levetiracetam was stopped and replaced with lamotrigine. Patient dramatically improved over next two days and became asymptomatic.

Keywords: Levetiracetam; Psychosis; Juvenile Myoclonic Epilepsy

Bibliography

1. Surges R., et al. “Is levetiracetam different from other antiepileptic drugs?” Therapeutic Advances in Neurological Disorders 1 (2008): 13-24.
2. Dannaram S., et al. “Levetiracetam-induced acute psychotic episode”. Innovations in Clinical Neuroscience 9 (2012): 10-12.
3. Patsalos PN. “Pharmacokinetic profile of levetiracetam: toward ideal characteristics”. Pharmacology Therapy 85 (2000): 77-85.
4. Youroukos S., et al. “Acute psychosis associated with levetiracetam”. Epileptic Disorder 5 (2003): 117-119.
5. Delanty N., et al. “Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: Open-label, noncomparative, multicenter, long-term follow-up study”. Epilepsia 53 (2012): 111-119.

---

Copyright: © 2021 Abhishek Juneja and Kuljeet Singh Anand. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.